Median Technologies’ Post

BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology.  GTC will become an early technology access member of BioAI's global ecosystem of clinical laboratories.   Read the full PR https://lnkd.in/drez2sNM #Digitalpathology #AI #NGS

BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology.  GTC will become an early technology access member of BioAI's global ecosystem of clinical laboratories.   Read the full PR https://lnkd.in/drez2sNM #Digitalpathology #AI #NGS BioAI

Rosetta Omics is a French healthcare deeptech startup in a mission is to revolutionize precision medicine, starting with cancer, by integrating multiomics data from patient tumors, clinical records, and advanced machine learning/AI algorithms. Our innovative approach aims to enhance the prediction of treatment responses, providing physicians with critical insights to prescribe the most effective therapies for their patients at the right time to save lives and cost. At the moment, response rate at first line is very low and physicians need tools like ours to help them. Additionally, we are collaborating with pharmaceutical companies to discover new biomarkers and targets, aiding in drug discovery and patient stratification during clinical trials to accelerate the development of safe and effective cancer treatments. We have already initiated discussions with several leading pharmaceutical firms. Meet Rosetta Omics @ #Sachs_HTIF More Info @ https://lnkd.in/df5auS9k #HealthTech #DigitalHealth #MedTech #HealthTechInnovation #BigData #AI #HealthTechForum #PharmaTechnology #MedicalDevices #HealthcareTechnology #HealthTechInvestment #SALSW

BullFrog AI's Transformative Year: A Letter to Shareholders BullFrog AI Holdings, a tech-enabled drug development firm, issues a letter to shareholders detailing significant achievements in 2023. The company, utilizing AI and machine learning, successfully completed an $8.4 million IPO, secured a partnership with the Lieber Institute for Brain Development, demonstrated efficacy in its oncology program, initiated a pre-clinical study for an obesity drug, identified novel drug targets for colorectal cancer, strengthened intellectual property, and recorded its first earned revenue. BullFrog AI emphasizes its commitment to revolutionizing drug development, with a focus on AI-driven advancements and strategic partnerships. The CEO expresses gratitude for shareholder support and anticipates a promising future in 2024. Vin Singh #BullFrogAI #DrugDevelopment #AIinHealthcare #ShareholderLetter #AIInnovation

🌟 Exciting Announcement for the AI Driven Drug Discovery Summit! 🌟 We are thrilled to announce Jackie Hunter PhD DSc CBE FBPharmacolS FMedSci, CEO of OI Pharma Partners Ltd (formerly Pharmivation Ltd), as a distinguished speaker at this year's summit. Jackie will delve into the transformative role of AI in accelerating the development of personalized treatments for patients. Key topics Jackie will cover include:  🔹 The impact of the microbiome on drug responses, particularly in oncology.   🔹 Predicting microbiome-drug interactions across diverse populations, individuals, and tumor subtypes to advance precision medicine.   🔹 Utilizing AI in later stages of development to enhance patient selection and streamline trial timelines. Jackie brings a wealth of experience in pharmaceutical research and drug development, having led global R&D at GSK and served as CEO of various organizations. Her expertise spans collaborations with academia, industry partnerships, and leadership in digital health innovation. Don't miss this insightful session! View the agenda here to find out more - https://lnkd.in/e8S2H72T #AIDDD #AIDrivenDrugDiscovery #DrugDiscovery #AI

🛫 Artificial Intelligence (AI) and Drug Discovery👏 AI is defining high level collaboration and partnerships - watch it 👀 👁 Intellomx Joins Johnson & Johnson Innovation (JLABS) Intelligent OMICS Ltd (Intellomx), a leading biotechnology company that applies artificial intelligence (AI) to accelerate drug discovery, has entered in collaboration with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to evaluate novel biological targets for the treatment of haematological cancers. The collaboration will combine Intellomx’s proprietary AI platform, which integrates multi-omics data and deep learning algorithms to uncover novel disease mechanisms and therapeutic opportunities for treatment, with Janssen's expertise in data science, oncology research and development. Share this strategic alliance with your network, hit the like button, comment to congratulate Robert Grundy, FRSB, Intelligent OMICS Ltd, and Janssen Research & Development, LLC Information brought to you by; follow our page at : MetaG1 Research Consortium, #metag1

Our friends at Adva Biotechnology use technologies from Lab Owl and InflexionPoint to automate autologous cell therapy for cancer treatments, taking personalized medicines to new heights. It's great to see articles like this discussing the tremendous benefits of data! Thanks to Michael Blechman for bringing this article to my attention. https://lnkd.in/ecUW7bCe

Attention, biotech and pharmaceutical pioneers! Our latest blog post unravels the thrilling 𝙍𝙚𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣 𝙞𝙣 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚: 𝙈𝙖𝙧𝙠𝙚𝙧-𝘿𝙧𝙞𝙫𝙚𝙣 𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 𝘿𝙧𝙪𝙜 𝘿𝙚𝙫𝙚𝙡𝙤𝙥𝙢𝙚𝙣𝙩. Discover how this cutting-edge approach is transforming healthcare! Dive into the realm of precision medicine, where treatments are tailored to your unique molecular profile. Uncover the secrets of biomarker-guided therapies that unlock personalized treatment plans. Read the full blog post here: https://lnkd.in/dmsx8Hyb 𝗖𝗼𝗻𝗻𝗲𝗰𝘁 𝘄𝗶𝘁𝗵 𝘂𝘀 𝘁𝗼𝗱𝗮𝘆! Let's explore the future of medicine, together! Contact us to discuss you oncology trial program: 𝗶𝗻𝗳𝗼@𝗸𝗮𝗽𝗮𝗱𝗶.𝗰𝗼𝗺 #MarkerDrivenRevolution #PrecisionMedicine #BiotechInnovation #Pharma #Biotech #Oncology #CancerResearch #MakeADifference #ClinicalTrials

Here is an interesting Blog on Marker-Driven Drug Development. Worth reading.

👁️🗨️ Big moves in #BioTech! Merck's $1.3B acquisition of EyeBio marks a pivotal push into the ophthalmology space with the Restoret treatment set for a milestone trial. 🚀 This strategic buy diversifies Merck's portfolio, beyond their realms of vaccines and cancer treatments, signaling a fresh vision in tackling retinal diseases. A perfect blend of innovation and patient need. 💡🩺 For the executive leaders in #MedTech, #HealthTech, #pharmaceuticals, and #BioTech - let's discuss the implications. How do you see such acquisitions shaping the future of patient care? 👇 #Merck #EyeBio #HealthcareInnovation